| 2.14 -0.01 (-0.47%) | 11-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.65 | 1-year : | 4.4 |
| Resists | First : | 3.12 | Second : | 3.76 |
| Pivot price | 2.76  |
|||
| Supports | First : | 2.08 | Second : | 1.73 |
| MAs | MA(5) : | 2.31 |
MA(20) : | 2.89 |
| MA(100) : | 3.31 |
MA(250) : | 4.52 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 7.3 |
D(3) : | 9.8  |
| RSI | RSI(14): 26.9 |
|||
| 52-week | High : | 15.26 | Low : | 2.08 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PTIX ] has closed above bottom band by 7.3%. Bollinger Bands are 20.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.19 - 2.21 | 2.21 - 2.22 |
| Low: | 2.05 - 2.07 | 2.07 - 2.09 |
| Close: | 2.11 - 2.14 | 2.14 - 2.17 |
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
Fri, 31 Oct 2025
Protagenic Therapeutics, Inc. Seeks Rescission of Share Exchange Agreement - TradingView
Fri, 22 Aug 2025
Biotech Protagenic Therapeutics Working to Maintain Nasdaq Compliance After Merger-Related Filing Delay - Stock Titan
Thu, 21 Aug 2025
PTIX Shares Surge 105%: What’s Happening with Protagenic Therapeutics? - Markets.com
Thu, 21 Aug 2025
Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders - ACCESS Newswire
Thu, 21 Aug 2025
Protagenic Therapeutics Stock Leaps: A Moment to Ponder? - timothysykes.com
Thu, 21 Aug 2025
Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phas - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 11.2 (%) |
| Held by Institutions | 10.1 (%) |
| Shares Short | 90 (K) |
| Shares Short P.Month | 11 (K) |
| EPS | -13.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.16 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.17 |
| PEG Ratio | 0 |
| Price to Book value | -1 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|